“Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine 6, no. 2 (March 4, 2022): s1. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/1516.